Analysts Set DexCom, Inc. (NASDAQ:DXCM) Target Price at $99.00

DexCom, Inc. (NASDAQ:DXCM) has been assigned an average rating of “Moderate Buy” from the twenty analysts that are covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $99.00.

DXCM has been the subject of a number of research analyst reports. Canaccord Genuity Group raised their price target on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and raised their target price for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Mizuho initiated coverage on shares of DexCom in a report on Thursday, April 10th. They issued an “outperform” rating and a $85.00 price target on the stock. Morgan Stanley increased their price target on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Finally, Citigroup lifted their price objective on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, March 4th.

DexCom Trading Down 0.2 %

Shares of DXCM opened at $68.59 on Friday. DexCom has a twelve month low of $57.52 and a twelve month high of $139.24. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $26.90 billion, a P/E ratio of 47.97, a PEG ratio of 2.30 and a beta of 1.50. The firm’s 50-day moving average is $74.98 and its two-hundred day moving average is $76.75.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, research analysts predict that DexCom will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock worth $8,044,178 in the last three months. Company insiders own 0.32% of the company’s stock.

Hedge Funds Weigh In On DexCom

A number of large investors have recently modified their holdings of the company. Norges Bank purchased a new stake in shares of DexCom during the 4th quarter worth about $385,367,000. Congress Asset Management Co. grew its stake in DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after buying an additional 1,332,522 shares during the period. Fisher Funds Management LTD acquired a new stake in shares of DexCom in the fourth quarter worth $96,507,000. Woodline Partners LP acquired a new stake in shares of DexCom in the fourth quarter worth $63,338,000. Finally, Northern Trust Corp raised its stake in shares of DexCom by 22.2% in the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company’s stock valued at $322,454,000 after acquiring an additional 753,857 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.